Search the Newsreel

iRhythm Technologies Inc (IRTC) Earnings Forecast: Future EPS & Revenue Growth Estimates

The article provides an earnings forecast for iRhythm Technologies Inc (IRTC), highlighting its current earnings forecast score, average price target, and analyst ratings. It indicates that 14 analysts currently rate IRTC as a "Strong Buy" with an average price target of $220.00. The company's …

Algorhythm Holdings Inc (RIME) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Algorhythm Holdings Inc (RIME), noting its current valuation score of 9.26, which ranks 10th in its industry. It highlights the company's P/E ratio of -0.20 and indicates that relevant data for P/B, P/S, and P/CF ratios have …

Algorhythm Holdings Inc (RIME) Institutional Confidence

This article provides an "Institutional Confidence" score for Algorhythm Holdings Inc (RIME) from TradingKey. It displays the current score, previous score, and a list of major shareholders with their shareholdings and percentage changes. The data shows insights into institutional activity and holdings for the …

Study Data Show Short-Term Holter Monitoring Misses AF Recurrence Post-Ablation in Pregnancy

New real-world study data from iRhythm Holdings Inc. indicate that short-term Holter monitoring often misses atrial fibrillation (AF) recurrence post-ablation and other arrhythmias in pregnant patients. The findings, presented at HRS 2026, suggest a shift towards continuous 14-day monitoring with devices like iRhythm's Zio …

IRTC|iRhythm Technologies Inc|Price:108.010|Chg%:+0.340

This article provides an in-depth analysis of iRhythm Technologies Inc. (IRTC), highlighting its relatively healthy fundamentals, high growth potential, and "Strong Buy" analyst rating with a target price of $178.00. Despite recent stock market underperformance, the company's valuation is considered fair within its industry, …

Acrophyte Hospitality Trust Closes Sale of US Hotel; Shares Up 7%

Kuehn Law Encourages Investors of Rhythm Pharmaceuticals, Inc. to Contact Law Firm

Kuehn Law, a shareholder litigation law firm, is investigating potential breaches of fiduciary duties by officers and directors of Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) due to alleged self-dealing. The firm is encouraging long-term RYTM stockholders to contact them for a free consultation regarding potential …

RYTM stock trades around recent range as Rhythm Pharmaceuticals highlights setmelanotide growth

Rhythm Pharmaceuticals (RYTM) stock is trading within its recent range as the company reports double-digit revenue growth for its rare obesity therapy, setmelanotide. Q1 2026 revenue reached $29 million, up 38% year-over-year, driven by increased patient uptake. While the company remains loss-making, its operating …

Rhythm Pharmaceuticals schedules live Q2 results webcast Aug. 4

Rhythm Pharmaceuticals (Nasdaq: RYTM) will report its second-quarter 2026 financial results and provide a corporate update during a live conference call and webcast on Tuesday, August 4, 2026, at 8:00 a.m. ET. The company, a commercial-stage biopharmaceutical firm, focuses on rare neuroendocrine diseases, with …

Rhythm Pharmaceuticals to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026

Rhythm Pharmaceuticals, Inc. announced it will host a conference call and webcast on Tuesday, August 4, 2026, at 8:00 a.m. ET to discuss its second quarter 2026 financial results and provide a corporate update. The company is a commercial-stage biopharmaceutical firm focused on rare …

Rhythm Pharmaceuticals, Inc. (RYTM) Investor Outlook: Strong Buy Ratings Signal Potential 31% Upside

Rhythm Pharmaceuticals, Inc. (RYTM) is a biopharmaceutical company focusing on treatments for rare neuroendocrine diseases, driving investor interest with strong analyst ratings and growth potential. Despite current negative EPS and high R&D costs, its 83.8% revenue growth and flagship product IMCIVREE in Phase 3 …

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against iRhythm Technologies, Inc. (IRTC) and Encourages Investors to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential corporate wrongdoing by iRhythm Technologies, Inc. (IRTC) and its officers/directors. Investors who purchased iRhythm securities before January 11, 2022, and still hold them, are encouraged to participate in the investigation by visiting the …

Frontier tech research, news & data

The article provides interest coverage data for Algorhythm Holdings, Inc. (RIME), noting that its interest coverage was — in FY2025 and on a trailing-twelve-month basis as of Q1 FY26. It further details the company's annual and quarterly interest coverage ratios from FY2009 to Q1 …

Technical Reactions to IRTC Trends in Macro Strategies

This article provides a technical analysis of Irhythm Technologies Inc. (NASDAQ: IRTC), highlighting near-term weak sentiment that may lead to a resumption of long-term weakness. It identifies a significant risk-reward short setup and offers three distinct AI-generated trading strategies with specific entry, target, and …

Form PRE 14A Algorhythm Holdings Inc For: 17 July By Investing.com

This article from Investing.com reports the filing of Form PRE 14A by Algorhythm Holdings Inc. on July 17. The brief report indicates the company's filing without providing further details about the content of the form. The article also includes various market data and links …

Analysts Offer Insights on Healthcare Companies: Irhythm Technologies (IRTC), Merck & Company (MRK) and Viking Therapeutics (VKTX)

This article highlights recent bullish analyst ratings for three healthcare companies: Irhythm Technologies (IRTC), Merck & Company (MRK), and Viking Therapeutics (VKTX). Analysts from BTIG, Scotiabank, and Canaccord Genuity reiterated Buy ratings, providing price targets and noting potential upsides based on current stock levels. …

Law firm probes Rhythm Pharmaceuticals officers for possible self-dealing harming shareholders

Kuehn Law, PLLC is investigating officers and directors of Rhythm Pharmaceuticals, Inc. for alleged breaches of fiduciary duties through potential self-dealing. This investigation could result in damages for shareholders and corporate governance reforms. Long-term shareholders are advised to contact the law firm for a …

Is Rhythm Pharmaceuticals Poised for a Breakthrough in Hypothalamic Obesity

Rhythm Pharmaceuticals' drug, setmelanotide, shows promising Phase 3 results for acquired hypothalamic obesity (HO), targeting a potential FDA approval by March 20, 2026. This condition represents a significant unmet medical need with a substantial global patient population. Analysts project significant revenue growth for Rhythm …

Needham Maintains IRhythm Technologies(IRTC.US) With Buy Rating, Maintains Target Price $255

Needham has reiterated its Buy rating for iRhythm Technologies (IRTC.US) and maintained a target price of $255. This continuation of a positive outlook suggests the firm sees sustained value or growth potential in the company.

IRhythm Holdings to Report Second Quarter 2026 Financial Results on August 6, 2026

iRhythm Holdings, Inc. announced it will release its second-quarter 2026 financial results after market close on Thursday, August 6, 2026. The company will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss these results, with a live and archived …

Truist Adjusts Price Target on iRhythm Technologies to $160 From $174, Maintains Buy Rating

Truist has lowered its price target for iRhythm Technologies (IRTC) to $160 from $174, while reiterating a Buy rating on the stock. iRhythm Technologies is a digital healthcare company specializing in ambulatory cardiac monitoring services. The company recently increased its earnings guidance for the …

Wells Fargo Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $155

Wells Fargo has reiterated its Buy rating for Rhythm Pharmaceuticals (RYTM.US) and maintained its price target at $155. This continued positive outlook suggests the firm sees sustained value and growth potential for the pharmaceutical company.

iRhythm Technologies, Inc. (IRTC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential corporate wrongdoing by iRhythm Technologies, Inc. (NASDAQ:IRTC). The law firm encourages shareholders who purchased iRhythm securities before January 11, 2022, and still hold them, to contact them to assist with the investigation. The …

iRhythm’s Q2 Results Call Will Be Live After Aug. 6 Close

HyTerra Ltd Issues New Shares and Pursues Strategic Growth Opportunities

Hyterra Ltd Announces Quotation of 21.4 Million New Securities

Algorhythm says SemiCab gained new brands, $9.5M cash infusion

Does iRhythm (IRTC) Balancing a Revenue Beat With In-Line Guidance Recast Its AI Cardiac Story?

Rhythm Pharmaceuticals Stock On Fire: Up 28% With 12-Day Winning Streak

Algorhythm Holdings, Inc. Actuals & Estimates (NASDAQ:RIME)

RYTM Forecast — Price Target — Prediction for 2027

8-Day Rally Sends Rhythm Pharmaceuticals Stock Up 24%

Algorhythm Holdings, Inc. (RIME) Upgraded to Buy: Here's What You Should Know

Rhythm Pharmaceuticals: The Rare Obesity Platform Is Becoming A Commercial Engine

Algorhythm Holdings, Inc. Q1 2026 Earnings Call Summary

Algorhythm Holdings, Inc. 1Q 2026: Revenue $2.4M, EPS $(0.52) — 10-Q Summary